4 claim verifications about Cortisol Cortisol ×
“Ashwagandha supplementation effectively reduces stress and lowers cortisol levels in humans.”
Multiple systematic reviews and meta-analyses — including a 2025 BJPsych Open analysis of 15 studies — consistently show ashwagandha reduces perceived stress and cortisol levels compared to placebo. However, these benefits are best demonstrated in chronically stressed adults, not the general population. Evidence certainty is rated "low" with high heterogeneity across trials, at least one RCT found no cortisol effect in a specific subgroup, and long-term safety data remain limited. The claim is substantively supported but overstates universality.
“Adrenal fatigue syndrome is a recognized medical condition in which overworked adrenal glands produce insufficient cortisol.”
Every major medical authority — including the Endocrine Society, NIDDK, Mayo Clinic, and Cleveland Clinic — explicitly states that "adrenal fatigue" is not a recognized medical diagnosis and lacks scientific proof. A 2016 systematic review in a peer-reviewed journal found no substantiation for the concept. While adrenal insufficiency (e.g., Addison's disease) is a real condition involving low cortisol, it has distinct causes unrelated to the "overworked adrenals" mechanism described in the claim. The only sources supporting the claim come from low-authority integrative or commercial health websites.
“Consuming caffeine while cortisol levels are elevated reduces the stimulant effect of caffeine compared to when cortisol levels are not elevated.”
The available evidence does not support this claim as stated. Studies show that habitual caffeine use can blunt caffeine's ability to further raise cortisol levels — but this is a different outcome from caffeine's stimulant effect on alertness, which is primarily mediated through adenosine receptor blockade. No source in the evidence pool directly measures whether pre-existing elevated cortisol reduces caffeine's wakefulness or alertness properties. The claim conflates two distinct physiological pathways, creating a materially misleading impression.
“Elevated cortisol levels do not directly prevent fat loss in humans.”
This claim oversimplifies a highly context-dependent biological relationship. While cortisol can stimulate fat mobilization under certain acute conditions, peer-reviewed evidence shows that under chronic elevation — when insulin is typically co-elevated — cortisol promotes fat storage via lipoprotein lipase activation and reduces basal lipolysis. The blanket assertion that elevated cortisol "does not directly prevent fat loss" omits these critical mechanistic distinctions, leaving readers with a materially incomplete picture.